-- 根據塔斯尼姆通訊社週五引述知情人士消息報道,伊朗將只允許商船在滿足特定條件的前提下通過霍爾木茲海峽。 報道稱,一位知情人士表示,在巴基斯坦斡旋達成停火協議後,伊朗與美國最初達成的協議允許一定數量的船隻每天通過該海峽。 報道還稱,黎巴嫩停火失敗後,伊朗暫停了該通行計畫。 該知情人士表示,伊朗為通過霍爾木茲海峽的船隻設定了三項條件:僅限商船通行,禁止軍艦通行,並禁止運輸任何與敵對國家有關的貨物。 報告補充說,該知情人士還表示,船隻必須使用伊朗指定的航線,並與伊朗軍隊協調通行。 報道最後指出,重新開放通行仍取決於滿足各項前提條件,特別是黎巴嫩停火。伊朗認為,黎巴嫩停火是維持通過這條咽喉要道海上通道的關鍵因素。 消息人士警告稱,任何繼續實施海上封鎖的行為都將被視為違反停火協議,並可能導致霍爾木茲海峽航運再次中斷。 報道稱,伊朗外交部長阿巴斯·阿拉格奇表示,只要商船遵守伊朗港口和海事組織制定的協調航線,停火期間它們將享有完全通行權。 美國總統川普表示,霍爾木茲海峽對商業開放,但他補充說,針對伊朗的海上封鎖將持續到雙邊談判全面結束為止。已聯繫伊朗外交部尋求置評。 (市場動態新聞來自與全球市場專業人士的對話。這些資訊據信來自可靠來源,但可能包含傳聞和猜測。準確性無法保證。)
Related Articles
Morgan Stanley Downgrades AES to Equalweight From Overweight, Adjusts Price Target to $15 From $23
AES (AES) has an average rating of hold and mean price target of $15.12, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Compass Therapeutics Tovecimig Study Falls Short on Overall Survival Endpoint in Biliary Tract Cancer; Shares Fall Pre-Bell
Compass Therapeutics (CMPX) reported that its experimental drug tovecimig did not meet the overall survival secondary endpoint in a phase 2/3 study in patients with advanced biliary tract cancer, the company said Monday.Shares of the company fell more than 63% in recent pre-bell activity Monday.The company said that tovecimig plus paclitaxel did not show a statistically significant overall survival benefit versus chemotherapy alone, largely due to high crossover from the control arm and prolonged survival after switching to the drug.However, the study met other key endpoints, including statistically significant improvements in progression-free survival and overall response rate versus paclitaxel alone.Compass Therapeutics plans to meet with the US Food and Drug Administration to discuss the results ahead of a planned biologics license application submission, it added.Price: $1.91, Change: $-3.11, Percent Change: -63.35%
Gold Eases Early Even as the Dollar Falls Ahead of This Week's U.S. Interest Rate Decision
Gold prices eased early on Monday, remaining rangebound even as the dollar fell ahead of the Wednesday interest-rate announcement from the Federal Reserve.Gold for June delivery was last seen down US$26.50 to US$4,714.40 per ounce, remaining within the US$200 range it has been stuck in since the start of the war on Iran, as high oil prices raise concerns over higher inflation and threaten to boost interest rates.The Federal Open Market Committee (FOMC) will make its latest interest-rate decision at the Wednesday afternoon end to its two-day meeting. The CME FedWatch Tool sees a 100% probability the group will leave rates unchanged."Gold remains stuck in neutral within a broad USD 200 range around USD 4,750, with most intraday price action dictated by energy prices and the ebb and flow of headlines from the White House and the Middle East. The FOMC is widely expected to leave rates unchanged on Wednesday," Saxo Bank noted.The dollar was lower early, with the ICE dollar index last seen down 0.28 points to 98.26. Treasury yields rose, with the yield on the two-year note up 1.0 basis points to 3.801%, while the 10-year note was paying 4.321%, up 1.3 points.